Research
Molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through GSTP1 and PHD2 co-inhibition
eLife · By Agata N Makar ·
The Brief
- The study reports that molidustat targets a synthetic lethal vulnerability in APC-mutant colorectal cancer through co-inhibition of GSTP1 and PHD2.
- APC gene mutations are a defining feature of colorectal cancer and may create metabolic and stress adaptation requirements that could be exploited.
- Prolyl hydroxylase domain (PHD) inhibitors have been explored as a therapeutic approach, according to the abstract excerpt.
Why it matters
The work proposes a possible targeted strategy for APC-mutant colorectal cancer, a common defining mutation, by exploiting a synthetic lethal dependency. The provided excerpt does not describe clinical testing or results beyond the abstract.
Who’s affected
- colorectal cancer researchers
- cancer drug developers
- #colorectal cancer
- #apc mutation
- #synthetic lethality
- #prolyl hydroxylase
- #molidustat
- #gstp1
Mutations in the adenomatous polyposis coli (APC) gene are a defining feature of colorectal cancer (CRC) and impose metabolic and stress adaptation requirements that may create exploitable vulnerabilities. Prolyl hydroxylase domain (PHD) inhibitors have been explored as…